RTI Surgical Fills Void in Anterior Cervical Discectomy and Fusion Procedures

RTI Surgical (RTI), a global surgical implant company, announced today that its C-Plus Peek IBF System is now indicated for use with allograft, including its proprietary map3 cellular allogeneic bone graft.
 
“This indication is important news because it now gives surgeons options that they didn’t have before,” noted Brian Hutchison, RTI president and chief executive officer. “Previously, the C-Plus Peek IBF System was indicated for use with only autograft, but now surgeons have more options and can tailor treatment to each individual patient’s needs.”
 
The map3 cellular allogeneic bone graft supports the body’s innate healing mechanisms and provides the scaffold and signals to support bone growth. The implant contains the three essential elements of bone formation (cortical cancellous bone chips supply an osteoconductive scaffold, demineralized bone matrix demonstrates verified osteoinductive potential and MAPC-class cells, a specific type of stem cell provides osteogenic and angiogenic signals to support the bone healing process). The C-Plus Peek IBF System is a PEEK interbody fusion system that offers multiple options and features designed to provide stability and anatomic restoration, facilitating fusion, when used with autogenous bone graft, and/or allogenic bone graft comprised of cancellous, cortical, and/or corticocancellous bone graft, in anterior cervical discectomy and fusion (ACDF) surgery.
 
“We are pleased to have received this indication for the C-Plus system, which expands our product portfolio that can be used with one of our key product innovations, map3 cellular allogeneic bone graft,” Hutchison said. “We can now offer surgeons an all-inclusive RTI portfolio with C-Plus implants, map3 allograft and the Aspect Anterior Cervical Plate (ACP) System, proving once more our commitment to providing surgeons with integrated offerings to help their patients.”